Korean J Gynecol Oncol.  2006 Mar;17(1):15-21.

Neoadjuvant chemotherapy with mitomycin-C, vincristine and cisplatin (MVC) for patients with loco-regionally advanced cervical carcinoma

Affiliations
  • 1Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. ds123.bae@samsung.com

Abstract


OBJECTIVE
The efficacy and toxicity of neoadjuvant chemotherapy (NAC) with mitomycin-C, vincristine and cisplatin (MVC) were assessed in bulky cervical carcinoma patients.
METHODS
Forty-six patients with stage Ib2 to IIb bulky cervical cancer were treated with intravenous combination of mitomycin-C 10 mg/m2, vincristine 1 mg/m2 and cisplatin 75 mg/m2 every three weeks. After three cycles of NAC, the patients either underwent surgery or radiation therapy, depending on their suitability for radical hysterectomy.
RESULTS
All 46 patients enrolled in this study underwent surgery after NAC. Toxic nonhematologic reactions consisted primarily of grade 1-2 nausea and vomiting (86.8%) and the most common hematologic toxicity was anemia (59.6%). Clinical responses occurred in 82.6% (38/46) of patients, including 23.9% (11/46) with a complete response (CR) and 13.0% (6/46) with a pathologically determined complete response. For a median follow up period of 28 months, the 3-year disease-free and overall survival rates were 74.0% and 80.0%, respectively. Pathologically confirmed lymph node metastasis or parametrial involvement or an initial tumor size > or = 16 cm2 were associated with shorter disease-free survival (p=0.040, p=0.000, p=0.001, respectively). Adjuvant postoperative RT did not show a survival benefit in patients who had no indications for adjuvant therapy after surgery (p=0.970). Therefore, 26 patients (56.5%) could have been managed without RT; these patients traditionally require RT without the NAC protocol.
CONCLUSION
Intravenous administration of MVC as a NAC seems to be well tolerated and beneficial in patients with loco-regionally advanced cervical cancer.

Keyword

Neoadjuvant chemotherapy; Mitomycin-C; Vincristine; Cisplatin; Loco-regionally advanced cervical cancer

MeSH Terms

Administration, Intravenous
Anemia
Cisplatin*
Disease-Free Survival
Drug Therapy*
Follow-Up Studies
Humans
Hysterectomy
Lymph Nodes
Mitomycin*
Nausea
Neoplasm Metastasis
Survival Rate
Uterine Cervical Neoplasms
Vincristine*
Vomiting
Cisplatin
Mitomycin
Vincristine
Full Text Links
  • KJGO
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr